Leerink Partnrs Forecasts Equillium FY2029 Earnings

Equillium, Inc. (NASDAQ:EQ) – Leerink Partnrs issued their FY2029 EPS estimates for shares of Equillium in a report released on Friday, March 28th. Leerink Partnrs analyst T. Smith forecasts that the company will earn ($0.06) per share for the year. Leerink Partnrs currently has a “Hold” rating on the stock. The consensus estimate for Equillium’s current full-year earnings is $0.14 per share.

Separately, Leerink Partners reissued a “market perform” rating and set a $1.00 target price (down previously from $3.00) on shares of Equillium in a research report on Friday.

Equillium Price Performance

Shares of EQ stock opened at $0.41 on Monday. The company has a market cap of $14.36 million, a PE ratio of -2.90 and a beta of 1.87. Equillium has a 1 year low of $0.37 and a 1 year high of $2.43. The stock’s 50 day simple moving average is $0.76 and its two-hundred day simple moving average is $0.79.

Equillium (NASDAQ:EQ) last released its quarterly earnings results on Thursday, March 27th. The company reported ($0.16) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.22) by $0.06. Equillium had a negative net margin of 10.05% and a negative return on equity of 20.68%. The company had revenue of $4.39 million for the quarter.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Equillium stock. DCF Advisers LLC lifted its holdings in shares of Equillium, Inc. (NASDAQ:EQ) by 91.0% during the fourth quarter, according to its most recent disclosure with the SEC. The fund owned 62,947 shares of the company’s stock after acquiring an additional 29,985 shares during the period. DCF Advisers LLC owned approximately 0.18% of Equillium worth $47,000 at the end of the most recent quarter. 27.05% of the stock is currently owned by institutional investors and hedge funds.

About Equillium

Equillium, Inc, a clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. The company's lead product candidate is itolizumab (EQ001), a first-in-class monoclonal antibody that targets the immune checkpoint receptor CD6, which is in Phase III clinical trials for the treatment of acute graft-versus-host disease; completed Phase I clinical trial for the treatment of ulcerative colitis; and Phase I clinical trial for the treatment of lupus nephritis.